Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kymab Ltd
Lawyers say a UK Supreme Court ruling invalidating Regeneron’s patent claims on transgenic mice could have a “profound effect” on the validity of patent claims in the life science sector.
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared with the $686m companies raised in 2018 overall. Experts says this "rude health" should continue for the next two to three years, at least.
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
- Drug Discovery Tools
- Synthesis Technologies, Production Processes